Company news

PureTech Health PLC news in 2026

PureTech Health PLC's news releases, calls and decks from 2026, newest first.

View company

PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO

October 26, 2026

PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO

October 19, 2026

PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP

October 9, 2026

PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated

October 7, 2026

Holding(s) in Company

October 7, 2026

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

September 21, 2026

PRTC's Gallop: Positive FDA Meeting & Fast Track

September 21, 2026

PRTC's SPTX: New Positive Phase 1 GlyphAllo Data

September 9, 2026

PRTC's Celea: 2 Deupirfenidone Presentations at ERS

August 25, 2026

PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial

July 13, 2026

PRTC Launches Celea w/ $180M & Top Tier Syndicate

July 2, 2026

PRTC Launches Celea: $180M & Asset Transfer

July 2, 2026

PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data

June 9, 2026

Correction - Holding(s) in Company

May 15, 2026

PRTC To Showcase Deupirfenidone at ATS Conference

May 13, 2026

PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX

May 1, 2026

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

April 29, 2026

PRTC Voluntarily Delists Nasdaq Depositary Shares

April 29, 2026

PRTC's Seaport Adds Neuropsychiatry Veteran to BOD

April 27, 2026

PRTC's Gallop: Positive Ph1 Topline MDS & AML Data

April 22, 2026

PRTC's Seaport Files for Proposed Nasdaq IPO

April 13, 2026

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

April 2, 2026

PRTC Publishes Phase 2b Deupirfenidone IPF Results

April 2, 2026

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

April 2, 2026

PRTC's Seaport: Positive Topline Ph1 for GlyphAgo

April 2, 2026

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

March 25, 2026

PRTC’s Seaport: GlyphAllo Paper Published

March 25, 2026

PDMR Notification RSU Vesting

March 13, 2026

Total Voting Rights

March 2, 2026

PRTC to Present at Leerink Healthcare Conference

February 25, 2026

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

February 19, 2026

PRTC's Deupirfenidone Granted FDA & EU ODD for IPF

February 19, 2026

PureTech to Present at the JP Morgan Conference

January 6, 2026

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026